continued to see incredible take up from those in priority groups 1-9, with take up in some groups exceeding 95% for first doses
parhau i weld niferoedd anhygoel o grwpiau blaenoriaeth 1-9 yn manteisio ar y brechlyn, ac mewn rhai grwpiau mae mwy na 95% wedi cael eu dos cyntaf